Search - tctmd.com

Displaying 601 - 620 of 748

Sort: Relevancy | Date

News Daily News

Most Recurrent Ischemic Events After PFO Closure Related to Comorbidities

July 24, 2013

News Daily News

Meta-Analysis Provides Little Closure to PFO-Stroke Debate

Jason Kahn

July 24, 2013

News Daily News

Meta-análisis proporciona poco debate sobre el cierre para el accidente cerebrovascular por FOP

Jason Kahn

July 24, 2013

News Daily News

La Mayoría de Episodios Isquémicos Recurrentes tras el Cierre del FOP se asocian a Comorbilidades

July 24, 2013

News Daily News

El Apixaban No es Inferior a la Terapia Estándar en el Tratamiento de los Tromboembolismos Venosos Agudos

L.A. McKeown

July 05, 2013

News Daily News

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

L.A. McKeown

July 05, 2013

News Daily News

Se Hallan Varios Predictores de la Embolización Cerebral tras Implantar Stents Carotídeos Protegidos

Yael L. Maxwell

June 28, 2013

News Daily News

Dabigatran Reduces Hemorrhagic Stroke in A-fib Patients Across Ethnic Groups

June 26, 2013

News Daily News

El Dabigatran Reduce los ACV Hemorrágicos en Pacientes con FA de Cualquier Grupo Étnico

June 26, 2013

News Daily News

ROCKET AF: Heart Failure Does Not Weaken the Case for Rivaroxaban

Caitlin E. Cox

June 20, 2013

News Daily News

Morbid Obesity: An Increasing Risk Factor in PCI Patients

L.A. McKeown

June 20, 2013

News Daily News

ROCKET AF: La Insuficiencia Cardíaca No Resta Validez del Rivaroxaban

Caitlin E. Cox

June 20, 2013

News Daily News

Obesidad Mórbida: Un Factor de Riesgo, en Aumento, en Pacientes con PCI

L.A. McKeown

June 20, 2013

News Daily News

PROTECT AF: 4-Year Results Show Superiority of Watchman Over Warfarin for A-fib

Yael L. Maxwell

May 17, 2013

News Daily News

PROTECT AF: Los Resultados a los 4 Años revelan la Superioridad del Watchman sobre la Warfarina contra la FA

Yael L. Maxwell

May 17, 2013

News Daily News

El Apixaban Superior a la Warfarin con independencia del Tipo y Duración de la FA

May 13, 2013

News Daily News

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

May 13, 2013

News Industry News

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

May 09, 2013

News Daily News

Population-Based Study Fails to Link PFOs to Increased Risk of CV Events

L.A. McKeown

May 03, 2013

News Daily News

Los ACV tras un cuadro de STEMI son Raros pero tienen Mal Pronóstico

Yael L. Maxwell

May 03, 2013

Advertisement

Most Recurrent Ischemic Events After PFO Closure Related to Comorbidities

Meta-Analysis Provides Little Closure to PFO-Stroke Debate

Meta-análisis proporciona poco debate sobre el cierre para el accidente cerebrovascular por FOP

La Mayoría de Episodios Isquémicos Recurrentes tras el Cierre del FOP se asocian a Comorbilidades

El Apixaban No es Inferior a la Terapia Estándar en el Tratamiento de los Tromboembolismos Venosos Agudos

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

Se Hallan Varios Predictores de la Embolización Cerebral tras Implantar Stents Carotídeos Protegidos

Dabigatran Reduces Hemorrhagic Stroke in A-fib Patients Across Ethnic Groups

El Dabigatran Reduce los ACV Hemorrágicos en Pacientes con FA de Cualquier Grupo Étnico

ROCKET AF: Heart Failure Does Not Weaken the Case for Rivaroxaban

Morbid Obesity: An Increasing Risk Factor in PCI Patients

ROCKET AF: La Insuficiencia Cardíaca No Resta Validez del Rivaroxaban

Obesidad Mórbida: Un Factor de Riesgo, en Aumento, en Pacientes con PCI

PROTECT AF: 4-Year Results Show Superiority of Watchman Over Warfarin for A-fib

PROTECT AF: Los Resultados a los 4 Años revelan la Superioridad del Watchman sobre la Warfarina contra la FA

El Apixaban Superior a la Warfarin con independencia del Tipo y Duración de la FA

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

Population-Based Study Fails to Link PFOs to Increased Risk of CV Events

Los ACV tras un cuadro de STEMI son Raros pero tienen Mal Pronóstico

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content